Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US
MANAMA, Kingdom of Bahrain, Feb. 16, 2025 (GLOBE NEWSWIRE) -- The Bahrain…
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
– GOMEKLI is the first and only medicine approved for both adults…
SpringWorks Therapeutics Announces FDA Approval of GOMEKLI (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
– GOMEKLI is the first and only medicine approved for both adults…
The Largest Insurance Provider in Massachusetts Publishes Positive Reimbursement Policy for the Nerivio REN Wearable for Acute and Preventive Treatment of Migraine
BRIDGEWATER, N.J. and NETANYA, Israel, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Theranica,…
Datar Cancer Genetics Unveils Next Generation Multi-Analyte, AI-Powered Decision Support Platform for Personalized Treatment of Difficult-to-Treat Cancers.
LONDON, MUNICH and NEW DELHI, Feb. 3, 2025 /PRNewswire/ -- Datar Cancer Genetics…
Smith+Nephew and UFC to host first-of-its-kind medical education course for treatment of injuries in combat sport athletes
Healthcare professionals are invited to register for the livestream option as a…
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Sarclisa is the first anti-CD38 treatment approved in China for patients with…
Comanche Biopharma Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia
January 30, 2025 05:00 ET | Source: Comanche Biopharma ILAP aims to…
Outlook Therapeutics Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD
Data presented at Hawaiian Eye and Retina 2025 MeetingResults confirmed that intravitreal…
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results…